Virucidals Control the Presence of Covid in Mouth/Saliva
Author(s):
Giovanni Belcaro*, Ezio Bombardelli, Umberto Cornelli, Maria Rosaria Cesarone, Roberto Cotellese, Mark Dugall, Marcello Corsi, Beatrice Feragalli and Lars Rosenkvist
Summary: This pilot study evaluated the effects of some virucidals in vivo (RT-PCR swab test) to define the presence of COVID in the mouth saliva. With this model, if an asymptomatic subject is positive (in the mouth saliva, the first incubating medium), virucidals may be used and the positivity can re-evaluated to define their viral killing power.
Results: A progressive decrease in positivity in the swab samples was observed. Virucidals’ produced disappearance of positivity in most subjects at 3 days. All virucidals used in this pilot registry resulted effective. The pharmaceutical form seems to be important to assure persisting traces of the virucidal in the mouth. Phyrorelief possibly produced the longest action (>3 hours) due to its slower release. These observations indicate a significant effect of virucidals on the viral contamination of the mouth with a simple, cost-effective model. The lower presence of a virus charge may reduce contagiousness of most patients and possibly, the spread of viral material from the mouth. The effects on the evolution of COVID-19 on single patients is, unknown but virucidals may assume a significant community value in controlling spreading.